Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

Video

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.

Recent Videos
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Martin H. Voss, MD, an expert on kidney cancer
Martin H. Voss, MD, an expert on kidney cancer
Martin H. Voss, MD, an expert on kidney cancer
Martin H. Voss, MD, an expert on kidney cancer
Martin H. Voss, MD, an expert on kidney cancer
Guillermo Garcia-Manero, MD, an expert on MDS
Related Content